Show simple item record

dc.contributor.authorSafreed-Harmon, Kelly
dc.contributor.authorHetherington, Kristina L
dc.contributor.authorAleman, Soo
dc.contributor.authorAlho, Hannu
dc.contributor.authorDalgard, Olav
dc.contributor.authorFrisch, Tove
dc.contributor.authorGottfredsson, Magnus
dc.contributor.authorWeis, Nina
dc.contributor.authorLazarus, Jeffrey V
dc.date.accessioned2018-02-27T13:01:17Z
dc.date.available2018-02-27T13:01:17Z
dc.date.issued2018
dc.date.submitted2018
dc.identifier.citationPolicy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. 2018, 13 (1):e0190146 PLoS ONEen
dc.identifier.issn1932-6203
dc.identifier.pmid29381697
dc.identifier.doi10.1371/journal.pone.0190146
dc.identifier.urihttp://hdl.handle.net/2336/620485
dc.descriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Filesen
dc.description.abstractIn the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat.
dc.description.abstractFourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country.
dc.description.abstractStakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly.
dc.description.abstractThe Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.
dc.description.sponsorshipGilead Sciencesen
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790214/pdf/pone.0190146.pdf
dc.rightsArchived with thanks to PloS oneen
dc.subjectHepatitisen
dc.subjectSóttvarniren
dc.subjectLýðheilsaen
dc.subjectTMD12en
dc.subjectRES12en
dc.subject.meshCross-Sectional Studiesen
dc.subject.meshHepatitis Cen
dc.subject.meshHumansen
dc.subject.meshPrevalenceen
dc.subject.meshPublic Health Practiceen
dc.subject.meshScandinavian and Nordic Countriesen
dc.subject.meshSubstance Abuse, Intravenousen
dc.titlePolicy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.en
dc.typeArticleen
dc.contributor.department[ 1 ] Univ Copenhagen, Rigshosp, CHIP, Copenhagen, Denmark Show more [ 2 ] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain Show more [ 3 ] Karolinska Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden Show more [ 4 ] Helsinki Univ Hosp, Abdominal Ctr, Helsinki, Finland Show more [ 5 ] Akershus Univ Hosp, Dept Infect Dis, Lorenskog, Norway [ 6 ] Riksforeningen Hepatit C, Mankarbo, Sweden Show more [ 7 ] Univ Iceland, Fac Med, Sch Hlth Sci, Reykjavik, Iceland Show more [ 8 ] Landspitali Univ Hosp, Dept Internal Med, Div Infect Dis, Reykjavik, Iceland Show more [ 9 ] Copenhagen Univ Hosp, Dept Infect Dis, Hvidovre, Denmark Show more [ 10 ] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmarken
dc.identifier.journalPloS oneen
dc.rights.accessOpen Access - Opinn aðganguren
dc.departmentcodeTMD12, RES12
refterms.dateFOA2018-09-12T17:04:47Z
html.description.abstractIn the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat.
html.description.abstractFourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country.
html.description.abstractStakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly.
html.description.abstractThe Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.


Files in this item

Thumbnail
Name:
Policy ....pdf
Size:
2.018Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record